Reynolds L R, Kotchen T A
Arch Intern Med. 1979 Jun;139(6):651-3.
The population for this study included 186 patients who were treated between 1962 and 1977 for diffuse toxic goiter. Patients were divided into two groups according to the primary mode of therapy, which was either thioamides or sodium iodide I 131. Of 96 patients who were treated with primary drug therapy, only 16% experienced a prolonged remission (more than two years) of hyperthyroidism. Except for a greater likelihood of remission among patients with mild hyperthyroidism, no other clinical features of Graves' disease were predictive of the long-term response to drug therapy. Among the 90 patients who received primary sodium iodide I 131 therapy, those who were pretreated with thioamides required a higher total dose to achieve a cure (13.8 mCi vs 9.6 mCi) and had a lower initial incidence of hypothyroidism (54% vs 73%).
本研究的人群包括186例在1962年至1977年间接受弥漫性毒性甲状腺肿治疗的患者。根据主要治疗方式，患者被分为两组，主要治疗方式为硫代酰胺或碘化钠I 131。在96例接受初始药物治疗的患者中，只有16%的患者甲状腺功能亢进症获得了长期缓解（超过两年）。除轻度甲状腺功能亢进症患者缓解的可能性更大外，格雷夫斯病的其他临床特征均不能预测药物治疗的长期反应。在90例接受初始碘化钠I 131治疗的患者中，那些先用硫代酰胺预处理的患者需要更高的总剂量才能治愈（13.8毫居里对9.6毫居里），且甲状腺功能减退症的初始发生率较低（54%对73%）。
